I am a postdoctoral fellow in the lab of Arnold Kriegstein at the University of California, San Francisco (UCSF). I focus on applying single-cell genomics techniques to study the development of specific cell types of the human brain, as well as to understand how these cell types are affected in various diseases, especially autism. Before starting my work at UCSF, I did my PhD at the University of Miami focusing on genomic analysis of autism. I did my B.S. and MS at Moscow State University in my native Russia, where I worked on animal models of epilepsy and Alzheimer’s disease.
Dmitry Velmeshev
Postdoctoral Scholar
University of California, San Francisco
From this contributor
Single-cell analysis suggests brain signaling problems in autism
Recent advances in technology allow researchers to measure RNA that is contained within the nucleus of a single brain cell.
Single-cell analysis suggests brain signaling problems in autism
Explore more from The Transmitter
To understand decision-making, we need to truly challenge lab animals
Complex, multidimensional tasks that unfold over time could reveal how different brain areas work together to support decisions.
To understand decision-making, we need to truly challenge lab animals
Complex, multidimensional tasks that unfold over time could reveal how different brain areas work together to support decisions.
‘Overdue’ debate unfurls over neuroimaging method
After a January paper questioned the validity of an approach called lesion network mapping, its users are pressure testing their results.
‘Overdue’ debate unfurls over neuroimaging method
After a January paper questioned the validity of an approach called lesion network mapping, its users are pressure testing their results.
Nearly 400 compounds affect behaviors tied to autism-linked genes in zebrafish
Estropipate, paclitaxel and levocarnitine altered behaviors tied to SCN2A and DYRK1A variants specifically, a new open-source platform revealed.
Nearly 400 compounds affect behaviors tied to autism-linked genes in zebrafish
Estropipate, paclitaxel and levocarnitine altered behaviors tied to SCN2A and DYRK1A variants specifically, a new open-source platform revealed.